MX1 and Dravet syndrome: Overall, our study demonstrates that integrating blood-derived gene modules with population-scale genetic data uncovers coherent molecular signatures underlying DS comorbidities, identifies candidate biomarkers and therapeutic targets (e.g., ISG15, IFITs, MX1), and highlights the power of combining transcriptomic and genetic evidence to elucidate complex disease mechanisms.